Eliem Therapeutics Current Ratio vs. EBITDA
| ELYMDelisted Stock | USD 3.04 0.19 5.88% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 38.91810801 | Current Value 40.86 | Quarterly Volatility 7.35645378 |
For Eliem Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Eliem Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Eliem Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Eliem Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Eliem Therapeutics over time as well as its relative position and ranking within its peers.
Eliem |
Eliem Therapeutics EBITDA vs. Current Ratio Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Eliem Therapeutics's current stock value. Our valuation model uses many indicators to compare Eliem Therapeutics value to that of its competitors to determine the firm's financial worth. Eliem Therapeutics is rated below average in current ratio category among its peers. It is rated # 3 in ebitda category among its peers . At this time, Eliem Therapeutics' Current Ratio is very stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Eliem Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Eliem EBITDA vs. Current Ratio
Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Eliem Therapeutics |
| = | 17.48 X |
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Eliem Therapeutics |
| = | (13.65 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Eliem EBITDA Comparison
Eliem Therapeutics is currently under evaluation in ebitda category among its peers.
Eliem Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Eliem Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Eliem Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Eliem Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Eliem Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -2 K | -2.1 K | |
| Operating Income | -21.5 M | -22.5 M | |
| Net Loss | -39.2 M | -41.2 M | |
| Income Before Tax | -35.1 M | -36.9 M | |
| Total Other Income Expense Net | -13.7 M | -13 M | |
| Net Loss | -40.7 M | -42.8 M | |
| Net Loss | -35.1 M | -36.9 M | |
| Income Tax Expense | -21.5 K | -22.5 K | |
| Non Operating Income Net Other | -125.3 K | -131.6 K | |
| Net Interest Income | 4.6 M | 3.3 M | |
| Interest Income | 4.6 M | 3.3 M | |
| Change To Netincome | 8.5 M | 6.3 M | |
| Net Loss | (1.30) | (1.37) | |
| Income Quality | 0.59 | 0.79 | |
| Net Income Per E B T | 0.90 | 0.57 |
Eliem Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Eliem Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Eliem Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Eliem Therapeutics' important profitability drivers and their relationship over time.
Use Eliem Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eliem Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will appreciate offsetting losses from the drop in the long position's value.Eliem Therapeutics Pair Trading
Eliem Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Eliem Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eliem Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eliem Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eliem Therapeutics to buy it.
The correlation of Eliem Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eliem Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eliem Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eliem Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Eliem Therapeutics position
In addition to having Eliem Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Electronic Equipment Thematic Idea Now
Electronic Equipment
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Electronic Equipment theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Electronic Equipment Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Eliem Stock
If you are still planning to invest in Eliem Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eliem Therapeutics' history and understand the potential risks before investing.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |